ASLAN Pharmaceuticals Ltd - ADR

Aslan Pharmaceuticals Ltd. is a clinical-stage immunology biopharmaceutical company, which engages in the development of novel therapeutics. It focuses on atopic dermatitis, other immunology indications and autoimmune disease. Its pipeline includes ASLAN003 and Eblasakimab. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.

SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2020 and provided an update on its clinical activities.

ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

--   ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort

ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher

Ligand Pharmaceuticals

Eli Lilly

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal

--  ASLAN believe s ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease , more than 30 times more potent at inhibiting the DHODH enzyme than teriflunomide

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

SINGAPORE, Sept.  21, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis (AD) patients. Patients will now be recruited from 4 sites in Australia, 3 sites in the US alongside 2 existing sites in Singapore.

ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

SINGAPORE, Sept.  10, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference. Dr Carl Firth, Chief Executive Officer is scheduled to make a company presentation on 16 September 2020 at 9:00am EDT. The virtual conference will be held from 14-16 September 2020.

ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020 Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020

ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study

SINGAPORE, Aug.  07, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced its presentation at the BTIG Virtual Biotechnology Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, are scheduled to participate in a fireside chat on Monday, 10 August, 2020 at 09:00am ET. The conference will be held from 10-11 August 2020.

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020

SINGAPORE, Aug.  03, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer. Dr Kobayashi will be based in California and will be responsible for the global clinical development of ASLAN’s pipeline, including the lead program, ASLAN004, an antibody that blocks the IL-13 receptor, which is being developed for atopic dermatitis (AD).

ASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer

SINGAPORE, July  17, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced further progress towards a primary listing on the Nasdaq Global Market (“Nasdaq”) and receipt of a Notice of Delisting from the Taipei Exchange (“TPEx”), an expected step in the TPEx delisting process. The company will retain its listing of American Depositary Shares (“ADS”) on Nasdaq in the United States and existing holders of ADS do not need to take any action as a result of this announcement.

ASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's Why

SINGAPORE, July  13, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities.

ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

ASLAN Pharmaceuticals (ASLN) Looks Good: Stock Adds 8.7% in Session

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $1.92 in the latest trading session, marking a +0.26% move from the prior day.

ASLAN Pharmaceuticals Ltd. (ASLN) Gains As Market Dips: What You Should Know

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: Here's What You Should Know

In the latest trading session, ASLAN Pharmaceuticals Ltd (ASLN) closed at $1.65, marking a +0.61% move from the previous day.

ASLAN Pharmaceuticals Ltd (ASLN) Gains But Lags Market: What You Should Know

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

UPDATE - ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19

ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ASLAN Pharmaceuticals Ltd. (ASLN) Upgraded to Buy: What Does It Mean for the Stock?

SINGAPORE, March  18, 2020  (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the quarter and full year ended 31 December 2019 and provided an update on its clinical activities.

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.10, moving -1.87% from the previous trading session.

ASLAN Pharmaceuticals Ltd. (ASLN) Dips More Than Broader Markets: What You Should Know

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $2.11 in the latest trading session, marking a -0.94% move from the prior day.

ASLAN Pharmaceuticals Ltd. (ASLN) Stock Sinks As Market Gains: What You Should Know

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.

ASLAN Pharmaceuticals Ltd. (ASLN) Gains But Lags Market: What You Should Know

Is  (ASLN) Outperforming Other Medical Stocks This Year?

News for ASLAN Pharmaceuticals Ltd - ADR Stock (ASLN)